Background: Synergistic antitumor effects of the combined chemoimmunotherapy based on dendritic cells have been reported recently. The aim of this study is to search new applicability of gefitinib into the combination treatment through the confirmation of gefitinib effects on the monocyte derived dendritic cells (moDCs); most potent antigen presenting cell (APC). Methods: Immature and mature monocyte-derived dendritic cell (im, mMoDC)s were generated from peripheral blood monocyte (PBMC) in Opti-MEM culture medium supplemented with IL-4, GM-CSF and cocktail, consisting of TNF-α (10 ng/mL), IL-1β (10 ng/mL), IL-6 (1,000 U/mL) and PGE2 (1 μ/mL). Various concentrations of gefitinib also added on day 6 to see the influence on immature and mature MoDCs. Immunophenotyping of DCs under the gefitinib was performed by using monoclonal antibodies (CD14, CD80, CD83, CD86, HLA-ABC, HLA-DR 일부는 수지상세포의 성숙을 유도하고자 TNF-α (10 ng/mL, R&D Systems), IL-1β (10 ng/mL, R&D Systems), IL-6 (1,000 U/mL, R&D Systems), PGE 2 (1 μ/ mL, Sigma)의 혼합물을 첨가한 후 24시간 동안 더 배양하였 다. 성숙 수지상세포는 7일째 수확하였다.
